Excellergy

Excellergy is a private, pre-revenue biotech developing first-in-class trifunctional Effector Cell Response Inhibitors (ECRIs) for severe allergic diseases. Its platform targets the fundamental limitations of existing IgE-targeting therapies by directly removing IgE from mast cells and basophils without triggering activation, potently neutralizing free IgE, and driving receptor downregulation. Backed by $70M in Series A funding from top-tier investors and led by a seasoned CEO with a strong commercial track record, the company is advancing a portfolio of programs with the potential to redefine the standard of care in allergy treatment.

Trifunctional Effector Cell Response Inhibitors (ECRIs) that directly remove IgE from mast cells/basophils without activation, neutralize free IgE, and downregulate IgE receptors.

Excellergy competes in the IgE-targeted therapy space dominated by omalizumab (Xolair®) and newer entrants like ligelizumab. Its key differentiator is the direct disarming of already-armed effector cells, a mechanism not employed by competitors which primarily target free IgE. Success hinges on demonstrating superior clinical efficacy based on this distinction.